secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001437749-26-007839
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences enrolls first patients in thyroid cancer feasibility study of Vybrance nsPFA system
--------------------------------------------------------------------------------

- First-in-human cases completed at Sarasota Memorial and MD Anderson for T1N0M0 papillary thyroid microcarcinoma.
- Study is a multicenter, prospective feasibility trial; 30 patients planned across two sites.
- System has FDA 510(k) clearance for soft tissue ablation; study runs under IDE for thyroid indications.
- Primary endpoints: safety and effectiveness of nsPFA in treating tumors <1.5 cm.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926007839/0001437749-26-007839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926007839/plse20260309_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-007839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer